Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 10

1.

A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin 2, and interferon alpha-2B in patients with metastatic melanoma.

McDermott DF, Mier JW, Lawrence DP, van den Brink MR, Clancy MA, Rubin KM, Atkins MB.

Clin Cancer Res. 2000 Jun;6(6):2201-8.

2.

Biochemotherapy in the treatment of metastatic melanoma in selected patients.

González Astorga B, Jiménez Rubiano B, Delgado Pérez JR, Valdivia Bautista J, Sánchez Toro C, González Flores E, Luque Caro R, Castellón Rubio V.

Clin Transl Oncol. 2009 Jun;11(6):382-6. Review.

PMID:
19531453
4.

Management of metastatic cutaneous melanoma.

Buzaid AC.

Oncology (Williston Park). 2004 Oct;18(11):1443-50; discussion 1457-9. Review.

5.

High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993.

Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, Abrams J, Sznol M, Parkinson D, Hawkins M, Paradise C, Kunkel L, Rosenberg SA.

J Clin Oncol. 1999 Jul;17(7):2105-16. Review.

PMID:
10561265
6.

Systemic chemotherapy for the treatment of metastatic melanoma.

Li Y, McClay EF.

Semin Oncol. 2002 Oct;29(5):413-26. Review.

PMID:
12407507
7.
8.

Focus on FOCIS: interleukin 2 treatment associated autoimmunity.

Moschos SJ, Mandic M, Kirkwood JM, Storkus WJ, Lotze MT.

Clin Immunol. 2008 May;127(2):123-9. doi: 10.1016/j.clim.2008.02.011. Review.

PMID:
18405863
9.

Mechanisms and management of toxicities associated with high-dose interferon alfa-2b therapy.

Kirkwood JM, Bender C, Agarwala S, Tarhini A, Shipe-Spotloe J, Smelko B, Donnelly S, Stover L.

J Clin Oncol. 2002 Sep 1;20(17):3703-18. Review.

PMID:
12202672
10.

Engineering nanomedicines for improved melanoma therapy: progress and promises.

Bei D, Meng J, Youan BB.

Nanomedicine (Lond). 2010 Nov;5(9):1385-99. doi: 10.2217/nnm.10.117. Review.

Supplemental Content

Support Center